ATR
Bearish signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
AptarGroup, Inc.
- Nom
- AptarGroup, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NYSE
- Capitalisation
- $8.1B
- Employés
- 14,000
- PDG
- Gael Touya
- Site web
- https://www.aptar.com
- Marché
- AMCRSLGNSONSTVNTRSWST
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 9 838 titres (~1 339 588,32 $ US)
- Insiders
- Tanda Stephan B.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,695,341
Avg sell (VWAP, 90d window) $135.40 vs last close $119.91 (-11.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-03
- Liquidity
- Liquid $53,535,133/day · 20d vol
- Last synced
-
2026-10-02 21:10:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Vinczeller Shiela | Sell · S | 765 | $130.37 | $99,733 | Form 4 |
| 2026-08-27 | Touya Gael | Sell · S | 325 | $134.55 | $43,730 | Form 4 |
| 2026-08-04 | Prieur Marc | Sell · S | 124 | $137.10 | $17,000 | Form 4 |
| 2026-08-03 | Tanda Stephan B. | Sell · S | 9,838 | $136.16 | $1,339,588 | Form 4 |
| 2026-08-03 | Tlili Hedi | Sell · S | 8,854 | $135.00 | $1,195,290 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-18 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2026-06-12 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2025-11-19 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2025-09-22 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2025-09-11 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-08-26 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2023-11-01 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-11-01 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2022-08-08 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2022-08-08 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2019-09-13 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2019-09-11 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-07-12 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-03-05 | Bradley S. Schneider | Sale (Full) | $250,001 - $500,000 |
| 2019-02-26 | Elizabeth Fletcher | Sale (Full) | $1,001 - $15,000 |
| 2019-02-05 | Bradley S. Schneider | Purchase | $250,001 - $500,000 |
| 2018-12-17 | David B. McKinley | Sale (Full) | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ATR presents a moderately compelling setup: solid liquidity (75) and stable fundamentals (65) underpin a meaningful earnings catalyst (65) driven by a historic $1B+ revenue milestone in pharma and beverage segments…
The first sentence of the analysis written for ATR on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.62 · operating margin 14%
Suggested stop 116.39, nearest stored support minus 0.5 ATR(2.9% under the last close). Reward/risk to the next stored resistance is 0.89. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 29.6% | 37.8% | 36.2% | 35.0% | 35.8% | |
| Ebit Margin | 14.4% | 14.3% | 11.9% | 11.3% | 10.9% | |
| Ebitda Margin | 22.0% | 21.7% | 19.0% | 18.3% | 18.2% | |
| Operating Profit Margin | 13.6% | 13.9% | 11.6% | 11.4% | 10.8% | |
| Pretax Profit Margin | 13.0% | 13.1% | 10.7% | 10.1% | 10.0% | |
| Continuous Operations Profit Margin | 10.4% | 10.4% | 8.1% | 7.2% | 7.5% | |
| Net Profit Margin | 10.4% | 10.5% | 8.2% | 7.2% | 7.6% | |
| Bottom Line Profit Margin | 10.4% | 10.5% | 8.2% | 7.2% | 7.6% | |
| Current Ratio | 1.623 | 1.384 | 1.238 | 1.559 | 1.382 | |
| Quick Ratio | 1.162 | 0.952 | 0.828 | 1.029 | 0.933 | |
| Solvency Ratio | 0.268 | 0.328 | 0.250 | 0.222 | 0.222 | |
| Cash Ratio | 0.345 | 0.210 | 0.179 | 0.155 | 0.125 | |
| Price To Earnings Ratio | 20.429 | 27.805 | 28.484 | 30.049 | 32.925 | |
| Price To Earnings Growth Ratio | 3.607 | 0.921 | 1.533 | -18.630 | 2.733 | |
| Forward Price To Earnings Growth Ratio | 3.607 | 0.921 | 1.533 | -18.630 | 2.733 | |
| Price To Earnings Diluted Ratio | 20.741 | 28.409 | 29.087 | 30.635 | 34.022 | |
| Price To Earnings Diluted Growth Ratio | 3.277 | 0.943 | 1.582 | -110.286 | 2.800 | |
| Price To Book Ratio | 3.005 | 4.216 | 3.516 | 3.502 | 4.084 | |
| Price To Sales Ratio | 2.123 | 2.909 | 2.326 | 2.165 | 2.492 | |
| Price To Free Cash Flow Ratio | 26.763 | 29.841 | 31.582 | 44.128 | 144.887 | |
| Price To Operating Cash Flow Ratio | 14.066 | 16.197 | 14.101 | 15.029 | 22.128 | |
| Debt To Assets Ratio | 0.291 | 0.243 | 0.266 | 0.291 | 0.301 | |
| Debt To Equity Ratio | 0.574 | 0.435 | 0.514 | 0.595 | 0.632 | |
| Debt To Capital Ratio | 0.365 | 0.303 | 0.339 | 0.373 | 0.387 | |
| Long Term Debt To Capital Ratio | 0.299 | 0.218 | 0.228 | 0.339 | 0.315 | |
| Financial Leverage Ratio | 1.969 | 1.793 | 1.930 | 2.047 | 2.103 | |
| Working Capital Turnover Ratio | 6.643 | 10.120 | 8.599 | 7.476 | 6.693 | |
| Operating Cash Flow Ratio | 0.489 | 0.602 | 0.460 | 0.522 | 0.370 | |
| Operating Cash Flow Sales Ratio | 0.151 | 0.180 | 0.165 | 0.144 | 0.113 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.526 | 0.543 | 0.446 | 0.341 | 0.153 | |
| Debt Service Coverage Ratio | 1.849 | 1.784 | 1.150 | 3.143 | 1.609 | |
| Interest Coverage Ratio | 9.715 | 11.310 | 9.996 | 9.290 | 11.470 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.659 | 1.902 | 1.255 | 3.898 | 1.271 | |
| Operating Cash Flow Coverage Ratio | 0.372 | 0.598 | 0.486 | 0.392 | 0.292 | |
| Capital Expenditure Coverage Ratio | 2.108 | 2.187 | 1.807 | 1.516 | 1.180 | |
| Dividend Paid And Capex Coverage Ratio | 1.457 | 1.576 | 1.363 | 1.153 | 0.894 | |
| Dividend Payout Ratio | 0.308 | 0.305 | 0.364 | 0.416 | 0.404 | |
| Enterprise Value Multiple | 11.000 | 14.500 | 13.667 | 13.575 | 15.617 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 29.6% | ▼-8.2% | ▼-5.3% |
| Ebit Margin | 14.4% | ▲0.1% | ▲1.8% |
| Ebitda Margin | 22.0% | ▲0.3% | ▲2.2% |
| Operating Profit Margin | 13.6% | ▼-0.3% | ▲1.3% |
| Pretax Profit Margin | 13.0% | ▼-0.1% | ▲1.6% |
| Continuous Operations Profit Margin | 10.4% | ▼-0.1% | ▲1.6% |
| Net Profit Margin | 10.4% | ▼-0.1% | ▲1.6% |
| Bottom Line Profit Margin | 10.4% | ▼-0.1% | ▲1.6% |
| Current Ratio | 1.623 | ▲0.239 | ▲0.186 |
| Quick Ratio | 1.162 | ▲0.211 | ▲0.181 |
| Solvency Ratio | 0.268 | ▼-0.060 | ▲0.010 |
| Cash Ratio | 0.345 | ▲0.136 | ▲0.142 |
| Price To Earnings Ratio | 20.429 | ▼-7.377 | ▼-7.510 |
| Price To Earnings Growth Ratio | 3.607 | ▲2.686 | ▲5.574 |
| Forward Price To Earnings Growth Ratio | 3.607 | ▲2.686 | ▲5.574 |
| Price To Earnings Diluted Ratio | 20.741 | ▼-7.667 | ▼-7.837 |
| Price To Earnings Diluted Growth Ratio | 3.277 | ▲2.334 | ▲23.614 |
| Price To Book Ratio | 3.005 | ▼-1.211 | ▼-0.660 |
| Price To Sales Ratio | 2.123 | ▼-0.786 | ▼-0.280 |
| Price To Free Cash Flow Ratio | 26.763 | ▼-3.078 | ▼-28.677 |
| Price To Operating Cash Flow Ratio | 14.066 | ▼-2.131 | ▼-2.238 |
| Debt To Assets Ratio | 0.291 | ▲0.049 | ▲0.013 |
| Debt To Equity Ratio | 0.574 | ▲0.139 | ▲0.024 |
| Debt To Capital Ratio | 0.365 | ▲0.061 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.299 | ▲0.082 | ▲0.019 |
| Financial Leverage Ratio | 1.969 | ▲0.176 | ▲0.001 |
| Working Capital Turnover Ratio | 6.643 | ▼-3.477 | ▼-1.263 |
| Operating Cash Flow Ratio | 0.489 | ▼-0.114 | ▲0.000 |
| Operating Cash Flow Sales Ratio | 0.151 | ▼-0.029 | ▲0.001 |
| Free Cash Flow Operating Cash Flow Ratio | 0.526 | ▼-0.017 | ▲0.124 |
| Debt Service Coverage Ratio | 1.849 | ▲0.065 | ▼-0.058 |
| Interest Coverage Ratio | 9.715 | ▼-1.595 | ▼-0.641 |
| Short Term Operating Cash Flow Coverage Ratio | 1.659 | ▼-0.243 | ▼-0.338 |
| Operating Cash Flow Coverage Ratio | 0.372 | ▼-0.226 | ▼-0.056 |
| Capital Expenditure Coverage Ratio | 2.108 | ▼-0.079 | ▲0.348 |
| Dividend Paid And Capex Coverage Ratio | 1.457 | ▼-0.119 | ▲0.168 |
| Dividend Payout Ratio | 0.307 | ▲0.003 | ▼-0.052 |
| Enterprise Value Multiple | 11.000 | ▼-3.501 | ▼-2.672 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $8.02B | $10.42B | $8.11B | $7.19B | $8.04B | |
| Enterprise value | $9.15B | $11.27B | $9.07B | $8.27B | $9.16B | |
| EV / Sales | 2.42x | 3.15x | 2.60x | 2.49x | 2.84x | |
| EV / Op. cash flow | 16.05x | 17.52x | 15.77x | 17.29x | 25.21x | |
| EV / Free cash flow | 30.53x | 32.28x | 35.32x | 50.75x | 165.10x | |
| EV / EBITDA | 11.00x | 14.50x | 13.67x | 13.57x | 15.62x | |
| Net debt / EBITDA | 1.36x | 1.10x | 1.45x | 1.77x | 1.91x | |
| Current ratio | 1.62x | 1.38x | 1.24x | 1.56x | 1.38x | |
| Income quality | 1.45x | 1.72x | 2.02x | 2.00x | 1.49x | |
| Graham number | $74 | $69 | $59 | $51 | $50 | |
| Graham net-net | -$19 | -$15 | -$17 | -$19 | -$20 | |
| Tax burden | 79.9% | 79.7% | 75.9% | 71.5% | 75.9% | |
| Interest burden | 90.3% | 91.5% | 90.3% | 89.1% | 91.4% | |
| Working capital | $727.1M | $410.1M | $298.0M | $513.1M | $375.7M | |
| Invested capital | $3.80B | $3.11B | $3.08B | $3.18B | $3.05B | |
| Return on assets | 7.5% | 8.5% | 6.4% | 5.7% | 5.9% | |
| Operating ROA | 10.6% | 11.2% | 9.3% | 9.1% | 8.5% | |
| Return on tangible assets | 10.0% | 11.6% | 8.9% | 8.1% | 8.7% | |
| Return on equity | 14.7% | 15.2% | 12.3% | 11.7% | 12.4% | |
| Return on invested capital | 9.2% | 10.7% | 8.4% | 8.0% | 7.6% | |
| Return on capital employed | 12.5% | 14.8% | 12.6% | 11.5% | 11.0% | |
| Earnings yield | 4.9% | 3.6% | 3.5% | 3.3% | 3.0% | |
| Free cash flow yield | 3.7% | 3.4% | 3.2% | 2.3% | 0.7% | |
| Capex / Op. cash flow | 47.4% | 45.7% | 55.4% | 65.9% | 84.7% | |
| Capex / Depreciation | 94.1% | 111.5% | 128.1% | 135.0% | 131.1% | |
| Capex / Sales | 7.2% | 8.2% | 9.1% | 9.5% | 9.5% | |
| SG&A / Sales | 13.2% | 16.3% | 16.2% | 16.4% | 17.1% | |
| R&D / Sales | 2.8% | 0.0% | 0.0% | 0.0% | 3.1% | |
| Stock comp / Sales | 0.0% | 1.3% | 1.2% | 1.2% | 1.2% | |
| Intangibles / Total assets | 25.4% | 26.9% | 28.0% | 30.0% | 32.3% | |
| Days sales outstanding | 78d | 67d | 71d | 74d | 76d | |
| Days payables outstanding | 47d | 48d | 54d | 54d | 50d | |
| Operating cycle | 151d | 143d | 155d | 157d | 154d | |
| Cash conversion cycle | 105d | 94d | 101d | 103d | 103d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-05 AptarGroup Q2 Earnings Beat Estimates on Pharma & Beverage Growth ATR tops Q2 earnings and revenue estimates as pharma and beverage growth lift quarterly revenues above $1B for the first time despite margin pressure.
- 2026-08-04 AptarGroup, Inc. $ATR Stock Position Raised by California State Teachers Retirement System California State Teachers Retirement System grew its position in shares of AptarGroup, Inc. (NYSE: ATR) by 24.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,227 shares of the industrial products company''s stock after buying an additional 15,158
- 2026-08-04 AptarGroup, Inc. (NYSE:ATR) Receives Average Recommendation of “Moderate Buy” from Brokerages AptarGroup, Inc. (NYSE: ATR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month
- 2026-08-03 Why AptarGroup (ATR) International Revenue Trends Deserve Your Attention Review AptarGroup''s (ATR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
- 2026-07-31 AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript
- 2026-07-31 AptarGroup Q2 Earnings Call Highlights AptarGroup NYSE: ATR reported second-quarter sales growth across each of its three segments and adjusted earnings per share above its guidance range, supported by stronger-than-expected performance in its Pharma business. The company also said President and CEO Stephan Tanda will retire later this year, with President and CEO Designate Gael Touya set to assume the CEO role on Sept.
- 2026-07-30 AptarGroup (ATR) Tops Q2 Earnings and Revenue Estimates AptarGroup (ATR) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $1.66 per share a year ago.
- 2026-07-28 AptarGroup Inc (ATR) Stock Up 3.3% and Still Undervalued -- GF Score: 82/100 On July 28, 2026, AptarGroup Inc (ATR) shares rose 3.3% to a current price of $137.81. The stock has experienced a 52-week range of $103.23 to $159.60, reflecti
- 2026-07-27 Aptar Named One of the World''s Most Sustainable Companies by TIME for Third Consecutive Year CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has been named one of the World''s Most Sustainable Companies 2026 by TIME for the third consecutive year. Aptar is ranked 261 out of 750 global companies evaluated by TIME and its partner Statista.
- 2026-07-26 First Trust Advisors LP Acquires 160,763 Shares of AptarGroup, Inc. $ATR First Trust Advisors LP grew its holdings in AptarGroup, Inc. (NYSE: ATR) by 42.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 538,554 shares of the industrial products company''s stock after acquiring an additional 160,763 shares during the period.